Dr. C. Sowmya

Pharmaceutical Product Development and Evaluation

Our research delves into the design and development of innovative plant-based drug delivery systems for chronic diseases such as cancers. We aim to utilize statistical Quality by Design (QbD) tools to optimize the product development.

Specifically, we develop dosage forms for conditions like breast and skin cancers, and psychotic depression, including:

• Niosomes
• In-situ gels
• Bilayer tablets

These disorders were selected based on their prevalence and significant impact on patients’ quality of life. Developing novel dosage forms for these cancers can enhance patients’ quality of life by reducing side effects and improving targeted delivery of chemotherapeutic agents. The use of dual drug delivery in bilayer tablets offers a promising approach to managing the symptoms of psychotic depression.

Additionally, our research focuses on the development of:

• Self-micro emulsifying drug delivery systems (SMEDDS)
• Solid lipid nanoparticles (SLNs)
• Emulgels
• Nano sponges
• Nanofibers

We conduct comprehensive characterization of the developed dosage forms, including drug release studies, kinetic modelling, and in vivo pharmacokinetic studies.

Furthermore, we develop topical emulgels to potentiate the efficacy of synthetic drugs through the incorporation of herbal constituents, offering an alternative to oral administration. Nanofiber formulations have been prepared successfully for augmented wound healing efficacy.